0.05Open0.05Pre Close0 Volume216 Open Interest12.00Strike Price0.00Turnover203.00%IV97.22%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0576Delta0.0495Gamma122.20Leverage Ratio-0.0100Theta0.0001Rho7.04Eff Leverage0.0013Vega
Recursion Pharmaceuticals Stock Discussion
Ghisallo Capital Management LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
• First program to combine Recursion's end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months
• Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient po...
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-in-Class Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
She makes millionaires out of her clients, they all started as multimillionaires.
if you think the AI story is just getting started, this is one field you must watch... it's a hugely...
No comment yet